This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You Looking for a Top Momentum Pick? Why Collegium Pharmaceutical (COLL) is a Great Choice
by Zacks Equity Research
Does Collegium Pharmaceutical (COLL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for February 29th
by Zacks Equity Research
UGP, HMC and COLL made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 29, 2023.
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q4 Earnings
by Zacks Equity Research
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Collegium Pharmaceutical (COLL) Could Beat Earnings Estimates Again
by Zacks Equity Research
Collegium Pharmaceutical (COLL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Collegium Pharmaceutical (COLL) Stock Might be a Great Pick
by Zacks Equity Research
Collegium Pharmaceutical (COLL) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Collegium (COLL) Shares Rise on Financial Outlook for 2024
by Zacks Equity Research
Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.
Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.28% and 1.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will US Business Strength Aid Acadia's (ACHC) Q2 Earnings?
by Zacks Equity Research
Strength in US operations, stemming from higher patient days and revenue per patient day, is expected to have aided Acadia Healthcare's (ACHC) Q2 performance. Rising expenses are likely to have partially offset the same.
Do Options Traders Know Something About Collegium Pharmaceutical (COLL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical (COLL) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Q1 Earnings Meet Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Lags Q1 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -11.67% and 2.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
by Zacks Equity Research
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.